Ledger W J
Am J Med. 1985 Jun 28;78(6B):194-203. doi: 10.1016/0002-9343(85)90384-5.
The future developments in the treatment of pelvic infections in women are based on recent changes. There is an expanded knowledge of the complex multibacterial nature of pelvic infections, the clinical view of salpingitis has radically changed, and there have been great modifications in antibiotic treatment strategies with particular emphasis on anaerobes and Chlamydia. In the next 10 years, the following new developments may be expected. In the diagnosis of pelvic infection, there will be new efforts to have better clinical tests and the use of nonspecific and specific laboratory tests. The rapid identification of Neisseria gonorrhea, group B beta-hemolytic Streptococcus, Chlamydia, and Bacteroides fragilis would be an important laboratory aid. The treatment of pelvic infection will not be significantly altered by the introduction of new antibiotics. There will be an emphasis on new combinations of currently available antibiotics and studies that focus on the long-term follow-up of treated patients. In the understanding of the pathophysiology of pelvic infections, the importance of the spermatozoa as a carrier of bacteria and the potent immunosuppression due to seminal fluid will be investigated in detail, along with a greater emphasis on treatment of the male.
女性盆腔感染治疗的未来发展基于近期的变化。人们对盆腔感染复杂的多细菌性质有了更广泛的认识,输卵管炎的临床观点发生了根本性变化,抗生素治疗策略也有了重大调整,尤其强调对厌氧菌和衣原体的治疗。在未来10年,可能会有以下新发展。在盆腔感染的诊断方面,将做出新的努力以获得更好的临床试验,并使用非特异性和特异性实验室检查。快速鉴定淋病奈瑟菌、B族β溶血性链球菌、衣原体和脆弱拟杆菌将是重要的实验室辅助手段。新抗生素的引入不会使盆腔感染的治疗发生显著改变。将强调现有抗生素的新组合以及专注于对治疗患者进行长期随访的研究。在对盆腔感染病理生理学的理解方面,将详细研究精子作为细菌载体的重要性以及精液引起的强大免疫抑制作用,同时更加重视男性的治疗。